Navigation Links
Clear Catheter Systems Completes $600-Million Financing, Opens Cleveland Office
Date:7/24/2008

BEND, Ore., and CLEVELAND, July 24 /PRNewswire/ -- Clear Catheter Systems (http://www.clearcatheter.com), formerly PleuraFlow, an early stage medical device company developing a proprietary medical catheter clearance platform, today announced the completion of a $600,000 financing round. The financing was led by X Gen Ltd, a family venture fund based in Cleveland, Ohio. It also includes a grant from the Cleveland Clinic Global Cardiovascular Innovation Center (GCIC) initiative, which is backed by $60-million from the State of Ohio's Third Frontier Project, a program to promote technical innovation and commercialization. BVC/CC, an angel group based in Bend, Oregon, also participated in the funding.

The funding will help Clear Catheter Systems develop its lead tube clearance product, the PleuraFlow System. The system will be used to prevent obstruction of surgical drainage tubes inserted after heart, lung and trauma surgery. Such obstruction, or clogging, has long remained an unsolved problem in surgery, with important implications for both patient safety and comfort.

"I've had patients say to me that the most memorable and painful part of heart surgery was the day their drainage tubes were pulled out," says Marc Gillinov, M.D., the Cleveland Clinic cardiothoracic surgeon who helped develop the PleuraFlow System. "We need to develop smaller tubes that drain the wound effectively, but don't hurt as much." Gillinov serves as Chairman of CCS's Scientific Advisory Board and as a consultant to the company.

"We are pleased to be collaborating with the Cleveland Clinic to develop and commercialize medical devices to improve outcomes after heart and other surgeries," said Edward Boyle, M.D., Clear Catheter Systems' CEO. "Clear Catheter's innovative technology addresses a large unmet need for surgical patients, allowing surgeons to deliver care in a safer, more minimally invasive fashion."

The company is in the process of opening a Cleveland office to better facilitate its collaboration with the Cleveland Clinic, and to access other resources available to the Ohio medical device community.

"Clear Catheter Systems is doing exciting work and we are pleased to be involved in the continued development of the PleuraFlow System," said Mark Low, GCIC Managing Director. "Cleveland Clinic and GCIC are committed to expanding Ohio's economy, and we welcome this growing company to Northeast Ohio."

About Clear Catheter Systems Inc.

Clear Catheter Systems, a development stage medical device company, founded in Bend, Oregon, is developing a proprietary medical tube clearance platform based on technology from the Cleveland Clinic and MDI Partners, a Bend, Oregon incubator. Clear Catheter's ultimate goal is to develop its tube clearance platform to help make surgery safer and more comfortable for heart, lung, trauma, and other patients.


'/>"/>
SOURCE Clear Catheter Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Nurses Send Sutter a Clear Message
3. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
4. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
5. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
6. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
7. Trade-offs reveal no clear favorites in alternative energy market
8. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
9. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
10. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
11. NDO Receives FDA 510(K) Clearance for Plicator II(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... Robert E. Burke, MD, PhD, had a successful career as a pediatrician ... could have led him down a much different path. , In his book, “Beyond ... Pediatrics,” Dr. Burke shares a personal account of the tribulations he encountered on his ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long ... company involved in the underground testing of nuclear weapons. Years later, when her co-workers ... of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... transplant clinic serving San Francisco and environs, is proud to announce an upgrade ... research information on the upgraded Yelp page on topics as diverse as Platelet ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
Breaking Medicine Technology: